184 related articles for article (PubMed ID: 30107003)
1. The vitamin D receptor gene as a determinant of survival in pancreatic cancer patients: Genomic analysis and experimental validation.
Innocenti F; Owzar K; Jiang C; Etheridge AS; Gordân R; Sibley AB; Mulkey F; Niedzwiecki D; Glubb D; Neel N; Talamonti MS; Bentrem DJ; Seiser E; Yeh JJ; Van Loon K; McLeod H; Ratain MJ; Kindler HL; Venook AP; Nakamura Y; Kubo M; Petersen GM; Bamlet WR; McWilliams RR
PLoS One; 2018; 13(8):e0202272. PubMed ID: 30107003
[TBL] [Abstract][Full Text] [Related]
2. A genome-wide association study of overall survival in pancreatic cancer patients treated with gemcitabine in CALGB 80303.
Innocenti F; Owzar K; Cox NL; Evans P; Kubo M; Zembutsu H; Jiang C; Hollis D; Mushiroda T; Li L; Friedman P; Wang L; Glubb D; Hurwitz H; Giacomini KM; McLeod HL; Goldberg RM; Schilsky RL; Kindler HL; Nakamura Y; Ratain MJ
Clin Cancer Res; 2012 Jan; 18(2):577-84. PubMed ID: 22142827
[TBL] [Abstract][Full Text] [Related]
3. 25-Hydroxyvitamin D levels and survival in advanced pancreatic cancer: findings from CALGB 80303 (Alliance).
Van Loon K; Owzar K; Jiang C; Kindler HL; Mulcahy MF; Niedzwiecki D; O'Reilly EM; Fuchs C; Innocenti F; Venook AP;
J Natl Cancer Inst; 2014 Aug; 106(8):. PubMed ID: 25099612
[TBL] [Abstract][Full Text] [Related]
4. Relevance of Sp Binding Site Polymorphism in WWOX for Treatment Outcome in Pancreatic Cancer.
Schirmer MA; Lüske CM; Roppel S; Schaudinn A; Zimmer C; Pflüger R; Haubrock M; Rapp J; Güngör C; Bockhorn M; Hackert T; Hank T; Strobel O; Werner J; Izbicki JR; Johnsen SA; Gaedcke J; Brockmöller J; Ghadimi BM
J Natl Cancer Inst; 2016 May; 108(5):. PubMed ID: 26857392
[TBL] [Abstract][Full Text] [Related]
5. A synthetic lethal screen identifies the Vitamin D receptor as a novel gemcitabine sensitizer in pancreatic cancer cells.
Bhattacharjee V; Zhou Y; Yen TJ
Cell Cycle; 2014; 13(24):3839-56. PubMed ID: 25558828
[TBL] [Abstract][Full Text] [Related]
6. A phase 3 randomized, double-blind, placebo-controlled trial of ganitumab or placebo in combination with gemcitabine as first-line therapy for metastatic adenocarcinoma of the pancreas: the GAMMA trial.
Fuchs CS; Azevedo S; Okusaka T; Van Laethem JL; Lipton LR; Riess H; Szczylik C; Moore MJ; Peeters M; Bodoky G; Ikeda M; Melichar B; Nemecek R; Ohkawa S; Świeboda-Sadlej A; Tjulandin SA; Van Cutsem E; Loberg R; Haddad V; Gansert JL; Bach BA; Carrato A
Ann Oncol; 2015 May; 26(5):921-927. PubMed ID: 25609246
[TBL] [Abstract][Full Text] [Related]
7. TAS-118 (S-1 plus leucovorin) versus S-1 in patients with gemcitabine-refractory advanced pancreatic cancer: a randomised, open-label, phase 3 study (GRAPE trial).
Ioka T; Ueno M; Ueno H; Park JO; Chang HM; Sasahira N; Kanai M; Chung IJ; Ikeda M; Nakamori S; Mizuno N; Omuro Y; Yamaguchi T; Hara H; Sugimori K; Furuse J; Maguchi H; Furukawa M; Fukuzawa K; Kim JS; Yukisawa S; Takeuchi M; Okusaka T; Boku N; Hyodo I
Eur J Cancer; 2019 Jan; 106():78-88. PubMed ID: 30471651
[TBL] [Abstract][Full Text] [Related]
8. Activation of Vitamin D/VDR Signaling Reverses Gemcitabine Resistance of Pancreatic Cancer Cells Through Inhibition of MUC1 Expression.
Wei D; Wang L; Liu Y; Hafley MA; Tan L; Lorenzi PL; Yang P; Zuo X; Bresalier RS
Dig Dis Sci; 2023 Jul; 68(7):3043-3058. PubMed ID: 37071246
[TBL] [Abstract][Full Text] [Related]
9. A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer.
Bramhall SR; Schulz J; Nemunaitis J; Brown PD; Baillet M; Buckels JA
Br J Cancer; 2002 Jul; 87(2):161-7. PubMed ID: 12107836
[TBL] [Abstract][Full Text] [Related]
10. Does health-related quality of life improve for advanced pancreatic cancer patients who respond to gemcitabine? Analysis of a randomized phase III trial of the cancer and leukemia group B (CALGB 80303).
Romanus D; Kindler HL; Archer L; Basch E; Niedzwiecki D; Weeks J; Schrag D;
J Pain Symptom Manage; 2012 Feb; 43(2):205-17. PubMed ID: 22104618
[TBL] [Abstract][Full Text] [Related]
11. Vitamin D receptor genetic variants are associated with chemotherapy response and prognosis in patients with advanced non-small-cell lung cancer.
Xiong L; Cheng J; Gao J; Wang J; Liu X; Wang L
Clin Lung Cancer; 2013 Jul; 14(4):433-9. PubMed ID: 23522953
[TBL] [Abstract][Full Text] [Related]
12. Association of serum level of vitamin D and VDR polymorphism Fok1 with the risk or survival of pancreatic cancer in Egyptian population.
Mohamed AA; Aref AM; Talima SM; A Elshimy RA; Gerges SS; Meghed M; Zahran FE; El-Adawy EH; Abd-Elsalam S
Indian J Cancer; 2019; 56(2):130-134. PubMed ID: 31062731
[TBL] [Abstract][Full Text] [Related]
13. Long term survivors with metastatic pancreatic adenocarcinoma treated with gemcitabine: a retrospective analysis.
Goulart BH; Clark JW; Lauwers GY; Ryan DP; Grenon N; Muzikansky A; Zhu AX
J Hematol Oncol; 2009 Mar; 2():13. PubMed ID: 19291303
[TBL] [Abstract][Full Text] [Related]
14. Contribution of FKBP5 genetic variation to gemcitabine treatment and survival in pancreatic adenocarcinoma.
Ellsworth KA; Eckloff BW; Li L; Moon I; Fridley BL; Jenkins GD; Carlson E; Brisbin A; Abo R; Bamlet W; Petersen G; Wieben ED; Wang L
PLoS One; 2013; 8(8):e70216. PubMed ID: 23936393
[TBL] [Abstract][Full Text] [Related]
15. An initial genetic analysis of gemcitabine-induced high-grade neutropenia in pancreatic cancer patients in CALGB 80303 (Alliance).
Innocenti F; Jiang C; Sibley AB; Denning S; Etheridge AS; Watson D; Niedzwiecki D; Hatch AJ; Hurwitz HI; Nixon AB; Furukawa Y; Kubo M; Crona DJ; Kindler HL; McLeod HL; Ratain MJ; Owzar K
Pharmacogenet Genomics; 2019 Aug; 29(6):123-131. PubMed ID: 30889042
[TBL] [Abstract][Full Text] [Related]
16. RNA sequencing of pancreatic adenocarcinoma tumors yields novel expression patterns associated with long-term survival and reveals a role for ANGPTL4.
Kirby MK; Ramaker RC; Gertz J; Davis NS; Johnston BE; Oliver PG; Sexton KC; Greeno EW; Christein JD; Heslin MJ; Posey JA; Grizzle WE; Vickers SM; Buchsbaum DJ; Cooper SJ; Myers RM
Mol Oncol; 2016 Oct; 10(8):1169-82. PubMed ID: 27282075
[TBL] [Abstract][Full Text] [Related]
17. High expression of survivin is prognostic of shorter survival but not predictive of adjuvant gemcitabine benefit in patients with resected pancreatic adenocarcinoma.
Xie H; Jiang W; Xiao SY; Liu X
J Histochem Cytochem; 2013 Feb; 61(2):148-55. PubMed ID: 23124118
[TBL] [Abstract][Full Text] [Related]
18. Pretreatment CA 19-9 level as a prognostic factor in patients with advanced pancreatic cancer treated with gemcitabine.
Saad ED; Machado MC; Wajsbrot D; Abramoff R; Hoff PM; Tabacof J; Katz A; Simon SD; Gansl RC
Int J Gastrointest Cancer; 2002; 32(1):35-41. PubMed ID: 12630768
[TBL] [Abstract][Full Text] [Related]
19. Combined analysis of intratumoral human equilibrative nucleoside transporter 1 (hENT1) and ribonucleotide reductase regulatory subunit M1 (RRM1) expression is a powerful predictor of survival in patients with pancreatic carcinoma treated with adjuvant gemcitabine-based chemotherapy after operative resection.
Nakagawa N; Murakami Y; Uemura K; Sudo T; Hashimoto Y; Kondo N; Sueda T
Surgery; 2013 Apr; 153(4):565-75. PubMed ID: 23253379
[TBL] [Abstract][Full Text] [Related]
20. Improved tumor control with antiangiogenic therapy after treatment with gemcitabine and nab-paclitaxel in pancreatic cancer.
Zhang Z; Ji S; Hu Q; Zhuo Q; Liu W; Xu W; Liu W; Liu M; Ye Z; Fan G; Xu X; Yu X; Qin Y
Clin Transl Med; 2021 Aug; 11(8):e398. PubMed ID: 34459132
[No Abstract] [Full Text] [Related]
[Next] [New Search]
